# Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer

> **NCT01025453** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 37 (actual)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Temsirolimus and Sorafenib

## Key facts

- **NCT ID:** NCT01025453
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-12-01
- **Primary completion:** 2018-01-16
- **Final completion:** 2018-01-16
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-08-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01025453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01025453, "Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01025453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*